Infectious Disease Daily Report: 01/17/2024

A phase 3 randomized study investigated the effect of 20-valent pneumococcal conjugate vaccine in 668 healthy Japanese infants and found that PCV20 SC or IM elicited immune responses expected to be protective against all 20 serotypes and had a similar safety/tolerability profile to PCV13 (1).

Reference

Ishihara Y, Fukazawa M, Enomoto S, de Solom R, Yamaji M, Kline M, Aizawa M, Peng Y, Kogawara O, Giardina PC, Tamimi N, Gruber WC, Watson W. A Phase 3 Randomized Study to Evaluate Safety and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants. Int J Infect Dis. 2024 Jan 17:S1201-9712(24)00010-9. doi: 10.1016/j.ijid.2024.01.009. Epub ahead of print. PMID: 38242195.